FDA approves Orca Bio's T-cell therapy to lower graft-versus-host disease risk in blood cancer transplants
read at STAT ↗ApprovalPositive
The FDA gave its nod to Orca Bio's personalized T-cell therapy, Tregzi, aimed at patients with blood cancers undergoing stem cell transplants.
The therapy is designed to cut the chance of chronic graft-versus-host disease, a serious immune complication that can follow matched-donor transplants.
Orca's CEO Nate Fernhoff called the approval a significant new option for leukemia patients, highlighting its potential to improve outcomes where traditional transplants carry high risk.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients”
read at STAT ↗562 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that